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Abstract 
Objective 
To report our experience on the safety and tolerability of moxifloxacin for treating 
children affected by pulmonary TB. 
Study Design 
Children receiving a moxifloxacin-containing anti-TB regimen were included in the 
study. Their medical records were revised at the end of follow-up. 
Methods 
We describe nine children treated with moxifloxacin for pulmonary TB at Regina 
Margherita Children's Hospital (Turin, Italy) between 2007 and 2012. Moxifloxacin 
was administered orally at 10 mg/kg/day once daily (maximum dose = 400 mg/day) 
following World Health Organization indications. During treatment, patients were 
systematically assessed for the development of side effects. 
Results 
Eight children were considered cured at the end of treatment; one child was lost to 
follow-up after 3 months of treatment. Two children had side effects during 
treatment: one developed arthritis of the ankle; the other had liver toxicity, whose 
relationship with moxifloxacin could not be ruled out. We did not observe any case of 
QT prolongation, central nervous system disorders, growth defects or gastrointestinal 
disturbances. 
Conclusions 
A moxifloxacin-containing regimen might be considered for the treatment of TB in 
children, especially for drug-resistant and extensive forms. However, vigilance for 
possible side effects is recommended, especially if other drugs are concomitantly 
used. Studies on wider populations are needed to better define the impact of long-
term treatments with quinolones on children's growth and psychomotor development 
and to outline regulatory indications on moxifloxacin use in the pediatric setting.  
 
INTRODUCTION 
Tuberculosis (TB) is a worldwide public health problem both in adults and in 
children. In industrialized countries, the epidemiology of TB has substantially 
changed over the last few decades, partly due to migration flows, with young 
immigrants from TB-endemic low-income countries being the most affected 
population. With an increasing number of new TB cases in young adults, especially 
among women of childbearing age, the incidence of TB in children has increased.[1] 
An additional emerging problem is the spread of Mycobacterium tuberculosis strains 
that are resistant to one or more anti-TB drugs.[2] In particular, strains resistant to 
both isoniazid and rifampin, defined as multidrug-resistant (MDR), are associated to 
an increased risk of treatment failure, further development of drug resistance and 
enhanced attributable mortality.[3] In Italy, the national surveillance system for TB 
reported in 2008 that 3.7% of strains were MDR, mainly isolated from patients 
between 15 and 34 years of age.[4] 
The inclusion in the anti-TB regimen of a later generation fluoroquinolone, such as 
levofloxacin or moxifloxacin, is recommended to treat isoniazid-resistant, rifampin-
resistant, or MDR-TB.[3] Indeed, the newer fluoroquinolones have improved 
pharmacokinetic properties compared with the older ones, in terms of longer serum 
half-life, higher peak levels, maximal bacterial killing, large volumes of distribution, 
and extensive tissue penetration.[5-7] On the contrary, ciprofloxacin is no longer 
recommended to treat patients with TB.[8] 
A fluoroquinolone-containing anti-TB regimen is also considered for pediatric 
patients with drug-resistant TB, albeit not licensed in this setting.[9-13] 
Moxifloxacin is a powerful second line anti-TB drug with some favorable properties, 
including a rapid sterilization activity on mycobacteria, low minimum inhibitory 
concentrations, readily achieved high peak levels in respiratory tissue and a once-
daily administration.[5, 6, 14, 15] At present, clinical data on its use in children are 
scanty, especially for TB patients. In general, quinolone use in pediatrics has been 
limited following the observation of arthrotoxicity in juvenile animals and is now 
mainly reserved for serious life-threatening infections for which alternative antibiotic 
therapies are not effective or available.[16, 17] The approved use of quinolones in 
children is limited to ciprofloxacin in specific situations, such as acute pulmonary 
exacerbations due to Pseudomonas aeruginosa in cystic fibrosis or complicated 
urinary tract infections.[18, 19] Few reports on the pediatric use of quinolones other 
than ciprofloxacin have been published, though providing encouraging efficacy and 
safety data.[1, 19-21] 
Aim of this series is to report our experience on the safety and tolerability of 
moxifloxacin for treating children affected by pulmonary TB. 
 
MATERIALS AND METHODS 
We describe nine children treated with a moxifloxacin-containing anti-TB regimen at 
our Center (Regina Margherita Children's Hospital, University of Turin, Turin, Italy) 
between 2007 and 2012. 
Moxifloxacin was administered orally at 10 mg/kg/day once daily (maximum 
dose = 400 mg/day) following World Health Organization indications.[10] When 
necessary, individualized doses were extemporaneously prepared at the pharmacy by 
crushing moxifloxacin tablets into powder. Patients were prospectively followed 
during treatment and systematically assessed for the development of side effects. 
ECGs were performed at baseline and monthly during treatment to monitor potential 
QT prolongation, along with clinical evaluation, growth assessment and laboratory 
testing including complete blood count and liver functionality tests. 
Diagnosis of pulmonary TB was made on the basis of epidemiological, clinical, and 
radiological findings, in accordance with World Health Organization criteria.[10] In 
all children at least three samples either of sputum or gastric aspirate were collected 
before treatment, at the end of the initial phase and before stopping therapy, in order 
to monitor treatment response. 
On each sample, the following tests were performed: microscopy for acid-fast bacilli 
(AFB) identification, culture on solid and automated liquid medium (BACTEC 
MGIT 960, Becton Dickinson, Franklin Lakes, NJ) and Nucleic Acid Amplification 
Tests with a commercial real-time PCR (MTB Q-PCR Alert, Nanogen, Advanced 
Diagnostics, Buttigliera Alta, Italy) for rapid identification of M. tuberculosis. 
Mycobacteria isolated from culture were identified with the molecular line probe 
assay GenoType MTBC (Hain LifeScience, Nehren, Germany). Pending culture 
results, rapid drug susceptibility testing (DST) of isoniazid and rifampin was 
performed with the molecular line probe assay GenoType MTBDRplus (Hain 
LifeScience) that identifies mutations in the rpoB gene for rifampin resistance, in the 
katG gene for high-level isoniazid resistance and in the inhA gene for low-level 
isoniazid resistance. In vitro DST to first-line drugs was performed using the 
resistance ratio method with the automated BACTEC MGIT 960 system (Becton 
Dickinson) with the following final drug concentrations: 1.0 and 6.0 µg/ml for 
streptomycin, 0.1 and 0.4 µg/ml for isoniazid, 1.0 µg/ml for rifampin, and 5.0 and 
7.5 µg/ml for ethambutol (EMB). Susceptibility testing for pyrazinamide, using a 
modified broth at pH 5.9, was performed with a final drug concentration of 
100 µg/ml. In case of resistant strains, second-line drugs susceptibility was tested 
with the same method at concentrations of 1.0 µg/ml for amikacin and linezolid, 
2.5 µg/ml for moxifloxacin and capreomycin, and 5.0 µg/ml for ethionamide. 
A patient was defined as cured at the end of treatment when all the following clinical, 
microbiological, and radiological criteria were satisfied: absence of signs and 
symptoms attributable to TB, at least three consecutive culture-negative respiratory 
samples during treatment, chest X-rays normalization. 
The study was performed in accordance with the ethical standards laid down in the 
1964 Declaration of Helsinki and National and Institutional standards. Parental 
written consent and permission of the local institutional review board for the 
individual off-label use of moxifloxacin and for collecting data for scientific purposes 
were obtained. 
RESULTS 
Nine children, aged 6 months to 13 years, received moxifloxacin as part of their TB 
treatment. Demographic, clinical, and microbiological data are summarized in 
Table 1. 
Table 1. Demographic, Clinical and Microbiological Characteristics of Children 
Treated With Moxifloxacin 
Patient 
number 
Sex 
Age at 
diagnosis 
HIV 
status 
Culture 
results at 
baseline 
Resistance 
of TB 
strain 
Total 
duration 
of TB 
treatment 
(months) 
Duration 
of 
therapy 
with 
MXF 
(months) 
1. N, negative; INH, isoniazid; RIF, rifampin; EMB, ethambutol; PZA, pyrazinamide; STR, streptomycin; AMK, amikacin; LZD, linezolid; ETO, ethionamide; PAS, 
para-aminosalicylic acid; CPR, ciprofloxacin. 
2. aConfirmed drug-resistant TB. 
3. bPresumed drug-resistant TB. 
4. cPresumed drug-susceptible TB. 
1 M 10 
months 
N Positivea INH, RIF, 
EMB, 
PZA, STR 
3.0 3.0 
2 F 15 
months 
N Positivea INH, STR 7.0 5.7 
3 M 6 months N Negativeb INH 7.7 7.4 
  
4 M 13 years N Positivea RIF, 
STR 
13.2 12.0 
5 F 3 years N Negativeb RIF 9.0 8.5 
6 F 6 years N Negativeb INH, 
STR 
7.5 4.0 
7 F 6 years N Positivea INH 7.7 3.4 
8 F 20 
months 
N Positivea INH, 
STR 
EMB, 
PRZ, 
RIF 
16.0 13.4 
9 F 6 year N Negativec None 6.8 4.0 
Moxifloxacin was prescribed due to the evidence of pulmonary drug-resistant TB 
(two MDR, one rifampin and streptomycin resistant, one isoniazid and streptomycin 
resistant and one isoniazid resistant-TB). One child (# 9) received moxifloxacin, even 
if affected by a presumed drug-susceptible TB, following a severe adverse reaction to 
isoniazid: she had vomiting, fever, shaking chills, and hypotension about 1 hr after 
the intake of the first two doses of isoniazid, after which the drug was discontinued. 
Five patients had AFB-positive cultures from sputum or gastric aspirates, on which 
DST was performed. Four children had repeatedly culture-negative respiratory 
samples (Table 1): in three of these patients drug resistance was presumed and 
treatment choice was directed by the DST of the source case (mother, father, and 
uncle, respectively, all with confirmed drug-resistant TB). In culture-positive patients 
all strains of M. tuberculosis were susceptible to moxifloxacin. In children suspected 
of having drug-resistant TB, the second line treatment was empirically started 
pending DST of second-line drugs and then modified according to DST results. 
The mean ± SD overall duration of the anti-TB treatment was 8.7 ± 3.8 months. 
Mean ± SD moxifloxacin administration was 6.8 ± 3.8 months. 
Children with isoniazid-resistant TB were treated for more than 6 months (mean 7.5, 
range 7–7.7 months) as recommended.[3] 
Two children had rifampin-resistant TB, for which the recommended treatment 
duration is 12–15 months.[3] One patient with presumed rifampin resistance had to 
prematurely discontinue treatment because of liver toxicity (see above); at that time 
the child was asymptomatic, gastric aspirates were negative and chest X-rays had 
been unremarkable since 4 months. A strict follow-up of the patient was conducted 
for the following 36 months. 
Of the two children with MDR-TB, one was lost to follow-up after 3 months of 
treatment; his chest X-ray showed a clear improvement of lung lesions after 2 months 
of therapy. The second child, with an early primary pulmonary TB, received 16 
months of therapy: the treatment duration was guided by the rapid clinical, 
microbiological, and radiological response of the patient (all findings normalized 
after 2 months of treatment) and by recent literature supporting shorter (12–15 
months) courses of therapy than what advised by WHO in selected pediatric 
patients.[22, 23] The baby was strictly monitored by clinical and radiological 
assessments and repeated gastric aspirates after treatment completion. 
In the five culture-positive patients, gastric aspirates and sputum samples were 
negative at microscopy, culture and molecular-line probe assays after about 2 months 
of treatment, and a chest X-ray showed complete healing at the end of treatment. In 
conclusion, all children were considered cured at the end of treatment, with the 
exception of the child lost to follow-up. 
Two children had side effects during treatment with moxifloxacin. One patient (# 5) 
had a grade three elevation of liver function tests after 9 months of treatment, at 
which point treatment was stopped. We recorded one case of arthritis of the ankle 
(patient #7) that appeared after 3 months of therapy with moxifloxacin; the symptoms 
spontaneously resolved few days after drug cessation. We did not observe any case of 
QT prolongation, central nervous system disorders, growth defects or gastrointestinal 
disturbances. 
The mean ± SD follow-up after treatment completion was 25.3 ± 9.5 months. During 
this period, no cases of relapse and no late-onset side effects attributable to anti-TB 
drugs, in particular to moxifloxacin, were recorded. 
 
DISCUSSION 
The role of later generation fluoroquinolones as second line agents in the treatment of 
drug-resistant TB has been widely recognized and an in vitro synergy with other anti-
tuberculous drugs has been reported.[24, 25] Moxifloxacin is increasingly used in 
adults as a second-line drug in the treatment of drug-resistant TB and a phase 3 trial 
evaluating the efficacy of a shortened first-line regimen including moxifloxacin for 
the treatment of drug-susceptible TB is also underway.[26] Compared to other 
quinolones, moxifloxacin has enhanced anti-mycobacterial activity, less potential of 
selecting resistance and obtained improved outcomes in patients with extensively 
drug-resistant TB.[27] It exerts concentration-dependent killing and has a favorable 
pharmacokinetic/pharmacodynamic profile, with sustained plasmatic and intracellular 
levels.[5] 
Despite its increasing use in adults, the clinical experience with moxifloxacin in 
children is limited and reports on its use for TB in children remain anecdotal. This 
partly comes from a restricted use of quinolonones in pediatrics because of their 
potential to induce cartilage toxicity.[19] Fluoroquinolones-induced arthralgia and/or 
arthritis is observed especially in adolescents treated with pefloxacin and, to a lesser 
extent, in children with cystic fibrosis receiving high doses of ciprofloxacin for long 
periods.[1] A case of severe, acute polyarthritis, associated with high doses of oral 
moxifloxacin, was recently documented in a 12-year-old child.[28] In our series, 
albeit limited, we observed one arthritis of the ankle in a child treated with 
moxifloxacin for 3 months: signs and symptoms of arthritis were mild and 
spontaneously resolved upon drug cessation. Liver toxicity was recorded in another 
patient, though it could not be certainly attributed to moxifloxacin as other 
hepatotoxic drugs were concomitantly used. Although the follow-up was relatively 
short, no impact on children's growth and psychomotor development was noticed. 
Treated patients showed a good response to various TB-combination therapies 
including moxifloxacin: with the exception of the child lost to follow-up, all children 
were radiologically and clinically cured at the end of treatment and all previously 
culture-positive patients became negative within 2 months of starting treatment. 
In conclusion, a moxifloxacin-containing regimen might be considered for the 
treatment of TB in children, especially in drug-resistant and extensive forms were an 
aggressive and prolonged treatment is needed. However, a strict vigilance in 
monitoring possible side effects is required. Further studies on different populations 
are needed to better define the impact of long-term treatments with quinolones in 
infants and children and to outline regulatory indications on their use in the pediatric 
setting. 
Ancillary 
 
REFERENCES 
 1Alghasham AA, Nahata MC. Clinical use of fluoroquinolones in 
children. Ann Pharmacother 2000; 34:347–359. 
 
 2Centers for Diseases Control and Prevention. Emergence of Mycobacterium 
tuberculosis with extensive resistance to second-line drugs: worldwide, 2000–
2004. MMWR 2006; 55:301–305. Available 
at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5511a2.htm. Accessed 
April 20, 2012. 
 
 3World Health Organization. Guidelines for the programmatic management of 
drug-resistant tuberculosis. Emergency update 2008. Geneva, Switzerland: 
World Health Organization; 2008. WHO/HTM/TB/2008.402. Available 
at: http://whqlibdoc.who.int/publications/2008/9789241547581_eng.pdf. 
Accessed April 20, 2012. 
 
 4Istituto Superiore di Sanità. Centro Nazionale di Epidemiologia, Sorveglianza 
e Promozione della Salute. Tubercolosi. Available 
at: htpp://www.epicentro.iss.it/problemi/Tubercolosi/Tb_Mdr-
Xdr.asp Accessed April 20, 2012. 
 
 5Angeby KA, Jureen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall 
M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. Wild-type 
MIC distributions of four fluoroquinolones active against Mycobacterium 
tuberculosis in relation to current critical concentrations and available 
pharmacokinetic and pharmacodynamic data. J Antimicrob 
Chemother 2010; 65:946–952. 
 
 6Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane 
T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B. Mitchison 
DA. Gatifloxacin for TB (OFLOTUB) study team. A phase II study of the 
sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary 
tuberculosis. Int J Tuberc Lung Dis2008; 12:128–138. 
 
 7Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra 
F. Fluoroquinolones for the treatment of pulmonary 
tuberculosis. Drugs 2007; 67:2077–2099. 
 8Ziganshina LE, Squire SB. Fluoroquinolones for treating 
tuberculosis. Cochrane Database Syst Rev 2008; 23:1–58. 
 
 9Schaaf HS, Marais BJ. Management of multidrug-resistant tuberculosis in 
children: a survival guide for paediatricians. Paediatr Respir Rev 2011; 12:31–
38. 
 
 10World Health Organization. Guidance for national tuberculosis programmes 
on the management of tuberculosis in children. Geneva, Switzerland: World 
Health Organization; 2006. WHO/HTM/TB/2006.371. Available 
at: http://whqlibdoc.who.int/hq/2006/WHO_HTM_TB_2006.371_eng.pdf. 
Accessed April 20, 2012. 
 
 11World Health Organization. Rapid advice. Treatment of tuberculosis in 
children. Geneva, Switzerland: World Health Organization; 2010. 
WHO/HTM/TB/2010.13. Available 
at: http://whqlibdoc.who.int/publications/2010/9789241500449_eng.pdf. 
Accessed April 20, 2012. 
 12Seddon JA, Hesseling AC, Marais BJ, McIlleron H, Peloquin CA, Donald 
PR, Schaaf HS. Paediatric use of second-line anti-tuberculosis agents: a 
review. Tuberculosis 2012; 92:9–17. 
 
 13Perez-Velez C. Pediatric tuberculosis: new guidelines and 
recommendations. Curr Op Pediatr 2012; 24:319–328. 
 
 14Conde MB, Efron A, Loredo C, De Souza GR, Graça NP, Cezar MC, Ram 
M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE. Moxifloxacin versus 
ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, 
controlled phase II trial. Lancet 2009; 373:1183–1189. 
 
 15Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach 
KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze 
R. Early and extended early bactericidal activity of levofloxacin, gatifloxacin 
and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung 
Dis 2006; 10:605–612. 
 
 16Ingham B, Brentnall D, Dale E, McFadzean J. Arthropathy induced by 
antibacterial fused N-Alkyl-4-pyridone-3-carboxylic acids. Toxicol 
Lett 1977; 1:21–26. 
 
 17Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals 
versus children. Clin Infect Dis 1997; 25:1196–1204. 
 
 18Committee on Infectious Diseases. The use of systemic 
fluoroquinolones. Pediatrics 2006; 118:1287–1292. 
 
 19Leibovitz E. The use of fluoroquinolones in children. Curr Opin 
Pediatr 2006; 18:64–70. 
 
 20Chauny JV, Lorrot M, Prot-Labarthe S, De Lauzanne A, Doit C, Géréral 
T, Bourdon O. Treatment of tuberculosis with levofloxacin or moxifloxacin: 
report of six pediatric cases. Pediatr Infect Dis J 2012; 31:1309–1311. 
 
 21Pinon M, Scolfaro C, Bignamini E, Cordola G, Esposito E, Milano 
R, Mignone F, Bertaina C, Tovo PA. Two pediatric cases of multidrug-resistant 
tuberculosis treated with linezolid and 
moxifloxacin. Pediatrics 2010; 126:e1253–e1256. 
 
 22Chiang C-Y, Schaaf HS. Management of drug-resistant tuberculosis. Int J 
Tuberc Lung Dis 2010; 14:672–682. 
 23Al-Dabbagh M, Lapphra K, McGloin R, Inrig K, Schaaf HS, Marais 
BJ, Sauve L, Kitai I, Kollmann TR. Drug-resistant tuberculosis. Pediatric 
guidelines. Pediatr Infect Dis J 2011; 30:501–505. 
 
 24Rastogi N, Goh KS, Bryskier A, Devallois A. In vitro activities of 
levofloxacin used alone and in combination with first- and second-line 
antituberculous drugs against Mycobacterium tuberculosis. Antimicrob Agents 
Chemother1996; 40:1610–1616. 
 
 25Gillespie SH, Gosling RD, Uiso L, Sam NE, Kanduma EG, McHugh 
TD. Early bactericidal activity of a moxifloxacin and isoniazid combination in 
smear-positive pulmonary tuberculosis. J Antimicrob 
Chemother 2005; 56:1169–1171. 
 
 26Clinicaltrials, gov. Controlled comparison of two moxifloxacin containing 
treatment shortening regimens in pulmonary tuberculosis (REMoxTB). March 
2009. Available 
at: http://clinicaltrials.gov/ct2/show/NCT00864383?term=moxifloxacin&rank=
1. Accessed April 20, 2012. 
 
 27Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB. Treatment 
outcomes among patients with extensively drug-resistant tuberculosis: 
systematic review and meta-analysis. Clin Infect Dis 2010; 51:6–14.|  
 
 28Torres JR, Bajares A. Severe acute polyarthritis in a child after high doses of 
moxifloxacin. Scand J Infect Dis2008; 40:582–584 
